Cannabis Authority Discusses Challenges with Medic
Post# of 94265
Posted On: 11/20/2013 9:05:14 AM
Cannabis Authority Discusses Challenges with Medical Marijuana Delivery
Prominent cannabis authority Ken Morrow recently discussed challenges associated with many current medical marijuana delivery systems.Morrow said, “Smoking marijuana is not appropriate for some patients, especially those with lung cancer or other respiratory ailments. Edibles are slow to take effect and are often not dose-standardized. Pills are also slow acting because they have to pass through the digestive system and are not a good option for someone who is nauseous.” He added, “Transmucosal products currently on the market are made from only one strain of marijuana.” Morrow pointed out diverse strains can target different ailments.Puget Technologies’ subsidiary, Cannabis Biotech, is investigating smoke-free delivery systems offering several benefits, including ease of use, portability, dosing accuracy and a wider variety of natural cannabis compounds.As previously announced, Cannabis Biotech’s medical marijuana product line will begin with a metered-dose transmucosal delivery system, a cannabis infused beverage line and transdermal patches.Learn more about Cannabis Biotech at http://www.cannabisbiotech.com.About Puget Technologies (PUGE)Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Product lines under development include B-29 Energy Drinks and several medical marijuana products through its subsidiary, Cannabis Biotech. Puget’s strategy is to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development to provide consumers with quality options while meeting the expectations of its investors.Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.Puget TechnologiesRon Leyland, 954-332-2471
Prominent cannabis authority Ken Morrow recently discussed challenges associated with many current medical marijuana delivery systems.Morrow said, “Smoking marijuana is not appropriate for some patients, especially those with lung cancer or other respiratory ailments. Edibles are slow to take effect and are often not dose-standardized. Pills are also slow acting because they have to pass through the digestive system and are not a good option for someone who is nauseous.” He added, “Transmucosal products currently on the market are made from only one strain of marijuana.” Morrow pointed out diverse strains can target different ailments.Puget Technologies’ subsidiary, Cannabis Biotech, is investigating smoke-free delivery systems offering several benefits, including ease of use, portability, dosing accuracy and a wider variety of natural cannabis compounds.As previously announced, Cannabis Biotech’s medical marijuana product line will begin with a metered-dose transmucosal delivery system, a cannabis infused beverage line and transdermal patches.Learn more about Cannabis Biotech at http://www.cannabisbiotech.com.About Puget Technologies (PUGE)Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Product lines under development include B-29 Energy Drinks and several medical marijuana products through its subsidiary, Cannabis Biotech. Puget’s strategy is to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development to provide consumers with quality options while meeting the expectations of its investors.Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.Puget TechnologiesRon Leyland, 954-332-2471
(0)
(0)